MedTrace Logo

Safety and Effectiveness of Transdermal Buprenorphine in Cancer Pain

NCT04315831 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 83

Last updated 2020-03-20

No results posted yet for this study

Summary

Buprenorphine transdermal patch is newly available in Taiwan in June 2017, the trade name is Transtec, and the available dosages are 35 μg/h and 52.5 μg/h. Taiwan is the first Asia country which launched Transtec for cancer pain treatment. Although the efficacy of transdermal buprenorphine has been demonstrated in some randomized, placebo-controlled studies and also conducted a large scale post-marketing surveillance study in Germany, therefore the local scientific data is required for Asia experience. Due to above rationale, this observational study will be initiated in Taiwan, to build up the first real-world scientific data in Asia.

The objective of this study is to collect the safety and effectiveness of transdermal buprenorphine in routine clinical practice, in particular, to collect data in population with controlled cancer pain and stable titration from previous opioid analgesics in Taiwan.

Conditions

Interventions

DRUG

Transdermal Buprenorphine

Intervention will be applied for patients with moderate to severe cancer pain

Sponsors & Collaborators

  • Chang Gung Memorial Hospital

    collaborator OTHER

  • Changhua Christian Hospital

    collaborator OTHER

  • Taipei Medical University Shuang Ho Hospital

    collaborator OTHER

  • Taiwan Mundipharma Pharmaceuticals Ltd.

    lead INDUSTRY

Principal Investigators

  • Jen-Shi Chen, MD · Chang Gung Memorial Hospital

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-31
Primary Completion
2019-03-31
Completion
2019-03-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04315831 on ClinicalTrials.gov